SNS-INSIDER-300X300.jpg
Venous Thromboembolism Treatment Market Size Expected to Attain US$ 2.13 Billion By 2032, Driven by Rising Pulmonary Embolism Cases & Cancer Incidence | SNS Insider
29 août 2024 09h00 HE | SNS Insider pvt ltd
Pune, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Venous Thromboembolism Treatment Market Size & Growth Analysis “The Venous Thromboembolism Treatment Market Size was valued at USD 1.05 Billion in 2023...
Zion Market Research.jpg
Global Venous Thromboembolism Treatment Market Size to Surge $10.3 Bn Growth by 2030, Exhibit a CAGR of 6.2%
12 sept. 2023 14h52 HE | Zion Market Research
Houston, TX, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Venous Thromboembolism Treatment Market By Product (Upper Pneumatic Compression...
logo 600X600.png
Global Low Molecular Weight Heparin Market to Surpass US$ 6,539.3 Million by 2030, Says Coherent Market Insights (CMI)
22 août 2022 09h30 HE | CMI
Seattle, Aug. 22, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global low molecular weight heparin market is estimated to be valued at US$ 3,903.1 million in 2022 and is...
Blood Clot Risk among People with Cancer
02 oct. 2019 09h35 HE | Stop the Clot, Spread the Word™
GAITHERSBURG, Md., Oct. 02, 2019 (GLOBE NEWSWIRE) -- The National Blood Clot Alliance (NBCA) and the Centers for Disease Control and Prevention (CDC) are rolling out a new suite of resources from...
VICA.png
Rafina Innovations Develops a Prototype Named Flexi Cuff for Deep Vein Thrombosis Patients
25 févr. 2019 10h30 HE | Rafina Innovations Inc.
GLASGOW, SCOTLAND, Feb. 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Rafina Innovations Inc. ("the Company" (OTCQB: VICA)) is pleased to announce that it has developed a product prototype to...
logo long.jpg
Global Rivaroxaban Market to Surpass US$ 7.0 Billion by 2026 – Coherent Market Insights
18 juil. 2018 09h00 HE | Coherent Market Insights
SEATTLE, July 18, 2018 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global rivaroxaban market was valued at US$ 5,653 in 2017 and is projected to exhibit a CAGR of 1.5% over the...